Base de dados : MEDLINE
Pesquisa : D12.776.124.486.274.350 [Categoria DeCS]
Referências encontradas : 4772 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 478 ir para página                         

  1 / 4772 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:29267496
[Au] Autor:Wu L; Wang X; Chen F; Lv X; Sun W; Guo Y; Hou H; Ji H; Wei W; Gong L
[Ad] Endereço:Department of Ultrasonography, Tianjin Medical University General Hospital, Tianjin, China.
[Ti] Título:T cell subsets and immunoglobulin G levels are associated with the infection status of systemic lupus erythematosus patients.
[So] Source:Braz J Med Biol Res;51(2):e4547, 2017 Dec 11.
[Is] ISSN:1414-431X
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:Systemic lupus erythematosus (SLE) is a chronic, autoimmune disorder that affects nearly all organs and tissues. As knowledge about the mechanism of SLE has increased, some immunosuppressive agents have become routinely used in clinical care, and infections have become one of the direct causes of mortality in SLE patients. To identify the risk factors indicative of infection in SLE patients, a case control study of our hospital's medical records between 2011 and 2013 was performed. We reviewed the records of 117 SLE patients with infection and 61 SLE patients without infection. Changes in the levels of T cell subsets, immunoglobulin G (IgG), complement C3, complement C4, globulin, and anti-double-stranded DNA (anti-ds-DNA) were detected. CD4+ and CD4+/CD8+ T cell levels were significantly lower and CD8+ T cell levels were significantly greater in SLE patients with infection than in SLE patients without infection. Additionally, the concentrations of IgG in SLE patients with infection were significantly lower than those in SLE patients without infection. However, complement C3, complement C4, globulin, and anti-ds-DNA levels were not significantly different in SLE patients with and without infection. Therefore, clinical testing for T cell subsets and IgG is potentially useful for identifying the presence of infection in SLE patients and for distinguishing a lupus flare from an acute infection.
[Mh] Termos MeSH primário: Imunoglobulina G/sangue
Infecção/sangue
Infecção/patologia
Lúpus Eritematoso Sistêmico/sangue
Lúpus Eritematoso Sistêmico/patologia
Subpopulações de Linfócitos T/patologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Anticorpos Antinucleares/sangue
Complemento C3/análise
Complemento C4/análise
Ensaio de Imunoadsorção Enzimática
Feminino
Citometria de Fluxo
Seres Humanos
Infecção/imunologia
Lúpus Eritematoso Sistêmico/imunologia
Masculino
Meia-Idade
Nefelometria e Turbidimetria
Reação em Cadeia da Polimerase
Fatores de Risco
Soroglobulinas/análise
Estatísticas não Paramétricas
Subpopulações de Linfócitos T/imunologia
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Antinuclear); 0 (Complement C3); 0 (Complement C4); 0 (Immunoglobulin G); 0 (Serum Globulins)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171222
[St] Status:MEDLINE


  2 / 4772 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28742139
[Au] Autor:Hovingh ES; van den Broek B; Kuipers B; Pinelli E; Rooijakkers SHM; Jongerius I
[Ad] Endereço:Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands.
[Ti] Título:Acquisition of C1 inhibitor by Bordetella pertussis virulence associated gene 8 results in C2 and C4 consumption away from the bacterial surface.
[So] Source:PLoS Pathog;13(7):e1006531, 2017 Jul.
[Is] ISSN:1553-7374
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Whooping cough, or pertussis, is a contagious disease of the respiratory tract that is re-emerging worldwide despite high vaccination coverage. The causative agent of this disease is the Gram-negative Bordetella pertussis. Knowledge on complement evasion strategies of this pathogen is limited. However, this is of great importance for future vaccine development as it has become apparent that a novel pertussis vaccine is needed. Here, we unravel the effect of Virulence associated gene 8 (Vag8) of B. pertussis on the human complement system at the molecular level. We show that both recombinant and endogenously secreted Vag8 inhibit complement deposition on the bacterial surface at the level of C4b. We reveal that Vag8 binding to human C1-inhibitor (C1-inh) interferes with the binding of C1-inh to C1s, C1r and MASP-2, resulting in the release of active proteases that subsequently cleave C2 and C4 away from the bacterial surface. We demonstrate that the depletion of these complement components in the bacterial surrounding and subsequent decreased deposition on B. pertussis leads to less complement-mediated bacterial killing. Vag8 is the first protein described that specifically prevents C1s, C1r and MASP-2 binding to C1-inh and thereby mediates complement consumption away from the bacterial surface. Unravelling the mechanism of this unique complement evasion strategy of B. pertussis is one of the first steps towards understanding the interactions between the first line of defense complement and B. pertussis.
[Mh] Termos MeSH primário: Proteínas de Bactérias/imunologia
Bordetella pertussis/imunologia
Complemento C1/imunologia
Complemento C2/imunologia
Complemento C4/imunologia
Fatores de Virulência de Bordetella/imunologia
Coqueluche/imunologia
[Mh] Termos MeSH secundário: Proteínas de Bactérias/genética
Bordetella pertussis/genética
Seres Humanos
Virulência
Fatores de Virulência de Bordetella/genética
Coqueluche/microbiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bacterial Proteins); 0 (Complement C1); 0 (Complement C2); 0 (Complement C4); 0 (Virulence Factors, Bordetella)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180209
[Lr] Data última revisão:
180209
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170726
[St] Status:MEDLINE
[do] DOI:10.1371/journal.ppat.1006531


  3 / 4772 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27772633
[Au] Autor:Heybeli C
[Ad] Endereço:Sarikamis State Hospital, Sarikamis, Turkey.
[Ti] Título:C4 Deposition in Glomerular Disease.
[So] Source:Am J Kidney Dis;68(5):817, 2016 11.
[Is] ISSN:1523-6838
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Complemento C4
Complemento C4b
[Mh] Termos MeSH secundário: Complemento C3
Seres Humanos
Glomérulos Renais
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Complement C3); 0 (Complement C4); 80295-50-7 (Complement C4b)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171129
[Lr] Data última revisão:
171129
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  4 / 4772 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27772631
[Au] Autor:Sethi S; Fervenza FC
[Ad] Endereço:Mayo Clinic, Rochester, Minnesota.
[Ti] Título:In Reply to 'C4 Deposition in Glomerular Disease'.
[So] Source:Am J Kidney Dis;68(5):817, 2016 11.
[Is] ISSN:1523-6838
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Complemento C4
Complemento C4b
[Mh] Termos MeSH secundário: Complemento C3
Seres Humanos
Glomérulos Renais
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Complement C3); 0 (Complement C4); 80295-50-7 (Complement C4b)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171129
[Lr] Data última revisão:
171129
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  5 / 4772 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28457114
[Au] Autor:Sthoeger Z; Lorber M; Tal Y; Toubi E; Amital H; Kivity S; Langevitz P; Asher I; Elbirt D; Agmon Levin N
[Ad] Endereço:Department of Internal Medicine B and Clinical Immunology, Allergy and Neve-Or AIDS Center, Kaplan Medical Center, Rehovot, Israel.
[Ti] Título:Anti-BLyS Treatment of 36 Israeli Systemic Lupus Erythematosus Patients.
[So] Source:Isr Med Assoc J;19(1):44-48, 2017 Jan.
[Is] ISSN:1565-1088
[Cp] País de publicação:Israel
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Anti-BLyS treatment with the human belimumab monoclonal antibody was shown to be a safe and effective therapeutic modality in lupus patients with active disease (i.e., without significant neurological/renal involvement) despite standard treatment. OBJECTIVES: To evaluate the "real-life" safety and efficacy of belimumab added to standard therapy in patents with active lupus in five Israeli medical centers. METHODS: We conducted a retrospective open-labeled study of 36 lupus patients who received belimumab monthly for at least 1 year in addition to standard treatment. Laboratory tests (C3/C4, anti dsDNA autoantibodies, chemistry, urinalysis and complete blood count) were done every 3-4 months. Adverse events were obtained from patients' medical records. Efficacy assessment by the treating physicians was defined as excellent, good/partial, or no response. RESULTS: The study group comprised 36 lupus patients (8 males, 28 females) with a mean age of 41.6 } 12.2 years. Belimumab was given for a mean period of 2.3 } 1.7 years (range 1-7). None of the patients discontinued belimumab due to adverse events. Four patients (11.1%) had an infection related to belimumab. Only 5 patients (13.9%) stopped taking belimumab due to lack of efficacy. The response was excellent in 25 patients (69.5%) and good/partial in the other 6 (16.6%). Concomitantly, serological response (reduction of C3/C4 and anti-dsDNA autoantibodies) was also observed. Moreover, following belimumab treatment, there was a significant reduction in the usage of corticosteroids (from 100% to 27.7%) and immunosuppressive agents (from 83.3% to 8.3%). CONCLUSIONS: Belimumab, in addition to standard therapy, is a safe and effective treatment for active lupus patients.
[Mh] Termos MeSH primário: Anticorpos Monoclonais Humanizados/uso terapêutico
Imunossupressores/uso terapêutico
Lúpus Eritematoso Sistêmico/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Autoanticorpos/sangue
Complemento C3/análise
Complemento C4/análise
DNA/imunologia
Feminino
Seres Humanos
Israel/epidemiologia
Lúpus Eritematoso Sistêmico/imunologia
Masculino
Infecções Oportunistas/epidemiologia
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Antibodies, Monoclonal, Humanized); 0 (Autoantibodies); 0 (Complement C3); 0 (Complement C4); 0 (Immunosuppressive Agents); 73B0K5S26A (belimumab); 9007-49-2 (DNA)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170501
[St] Status:MEDLINE


  6 / 4772 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28844428
[Au] Autor:Siskin M; Rao S; Rapkiewicz A; Bangalore S; Garshick M
[Ad] Endereço:Department of Medicine, NYU School of Medicine, New York, New York, USA.
[Ti] Título:A Case of Cardiogenic Shock Secondary to Complement-Mediated Myopericarditis From Influenza B Infection.
[So] Source:Can J Cardiol;33(10):1335.e1-1335.e3, 2017 Oct.
[Is] ISSN:1916-7075
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Influenza B is a rare cause of myocarditis that is usually caused by histiocytic and mononuclear cellular infiltrates. We describe a 22-year-old female patient presenting with fulminant myopericarditis secondary to influenza B infection that deteriorated to cardiogenic shock. Endomyocardial biopsy results yielded myocardial necrosis through complement-mediated cellular injury without evidence of interstitial infiltrates. The rare cause of this patient's disease, along with the unique pathologic findings, are an important reminder of the diversity of potential findings in myocarditis.
[Mh] Termos MeSH primário: Complemento C4/metabolismo
Influenza Humana/complicações
Miocardite/complicações
Pericardite/complicações
Choque Cardiogênico/etiologia
[Mh] Termos MeSH secundário: Biópsia
DNA Viral/análise
Eletrocardiografia
Feminino
Seres Humanos
Vírus da Influenza A/genética
Influenza Humana/diagnóstico
Influenza Humana/virologia
Miocardite/diagnóstico
Miocardite/metabolismo
Miocárdio/metabolismo
Miocárdio/patologia
Pericardite/diagnóstico
Pericardite/metabolismo
Choque Cardiogênico/diagnóstico
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Complement C4); 0 (DNA, Viral)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171026
[Lr] Data última revisão:
171026
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170829
[St] Status:MEDLINE


  7 / 4772 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28762539
[Au] Autor:da Silva Saraiva S; de Moraes Mazetto B; Quinteiro Tobaldine L; Pereira Colella M; Vinícius De Paula E; Annichinno-Bizzachi J; Andrade Orsi F
[Ad] Endereço:Thrombosis and Haemostasis Unit, Hematology and Hemotherapy Center, University of Campinas, Rua Carlos Chagas, 480. Cidade Universitária "ZeferinoVaz" CEP: 13083-970, Campinas, SP, Brazil.
[Ti] Título:The impact of antibody profile in thrombosis associated with primary antiphospholipid syndrome.
[So] Source:Am J Hematol;92(11):1163-1169, 2017 Nov.
[Is] ISSN:1096-8652
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Triple positivity (TP) for antiphospholipid antibodies(aPL) may identify aPL carriers with poorer prognosis. The clinical impact of TP in primary antiphospholipid syndrome(PAPS) remains unclear and further clinical evidences are needed to validate TP as a marker of severity. The aim of this study was to evaluate the impact of TP on the clinical course of PAPS with thrombosis(t-PAPS). We performed a retrospective analysis of a cohort of t-PAPS patients, comparing groups of patients with TP and non-TP profiles according to their demographic, clinical and laboratory features. We included 105 patients with t-PAPS, the median follow-up time of 3.7 years. Twenty-two patients(21%) had TP; the demographic distribution, the presence of cardiovascular risk factors and the site of thrombosis were similar between TP and non-TP patients. The frequency of thrombotic events did not differ between TP and non-TP patients during the study period. Pregnancy morbidities were more frequent in women with t-PAPS and TP than in those with non-TP profile (80% vs. 52.8%, P = 0.05). Patients with t-PAPS and TP presented, at diagnosis, higher dRVVT ratio (median R = 2.44 vs. 1.57, P < 0.0001), higher aCL titer (median = 50UI vs. 35 UI, P < 0.0001), lower C3 levels (median = 1.08 vs. 1.30 mg dL , P = 0.001), lower C4 levels (median = 0.22 vs. 0.25 mg dL , P = 0.05) and higher frequency of positive ANA test (50% vs. 20%, P = 0.008) than patients with t-PAPS and non-TP. Lower-than-normal levels of C3 was independently associated with TP (OR = 5.1, P = 0.02). The presence of TP in patients with t-PAPS was associated with immune derangement, with no effect on the clinical course of the disease.
[Mh] Termos MeSH primário: Anticorpos Antifosfolipídeos/imunologia
Síndrome Antifosfolipídica/complicações
Síndrome Antifosfolipídica/imunologia
Autoanticorpos/imunologia
Trombose/etiologia
[Mh] Termos MeSH secundário: Adulto
Síndrome Antifosfolipídica/diagnóstico
Biomarcadores
Comorbidade
Complemento C3/imunologia
Complemento C4/imunologia
Feminino
Seguimentos
Seres Humanos
Masculino
Meia-Idade
Gravidez
Complicações na Gravidez
Estudos Retrospectivos
Fatores de Risco
Trombose/diagnóstico
Trombose/mortalidade
Trombose/terapia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Antiphospholipid); 0 (Autoantibodies); 0 (Biomarkers); 0 (Complement C3); 0 (Complement C4)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171024
[Lr] Data última revisão:
171024
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170802
[St] Status:MEDLINE
[do] DOI:10.1002/ajh.24875


  8 / 4772 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28739769
[Au] Autor:Tang K; Sui LL; Xu G; Zhang T; Liu Q; Liu XF
[Ad] Endereço:Department of Hepatobiliary Surgery, Affiliated Yantai Yuhuangding Hospital, Qingdao University Medical College, Yantai, P.R. China.
[Ti] Título:Effects of Different Palliative Jaundice Reducing Methods on Immunologic Functions in Patients with Advanced Malignant Obstructive Jaundice.
[So] Source:Anticancer Res;37(8):4665-4670, 2017 08.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: This study aimed to investigate the effects of three treatment methods on the immunological function of patients with advanced malignant obstructive jaundice (MOJ). PATIENTS AND METHODS: Patients with advanced MOJ were randomly divided into three groups according to biliary drainage methods. Detection of levels of multi-indices were investigated in different time periods. RESULTS: After drainage, the levels of complement 3 (C3) and complement 4 (C4) were increased. Forteen days post-operation, the levels of immunoglobulin G (IgG), immunoglobulin A (IgA) and immunoglobulin M (IgM) in the group undergoing palliative surgery decreased significantly compared to those in both percutaneous transhepatic cholangio drainage (PTCD) and endoscopic retrograde biliary drainage (ERBD) groups. The level of serum endotoxin in the group undergoing palliative surgery decreased gradually. CONCLUSION: Palliative surgery for reducing jaundice is superior to PTCD and ERBD in improving immune function of patients with MOJ.
[Mh] Termos MeSH primário: Imunidade
Icterícia Obstrutiva/etiologia
Icterícia Obstrutiva/terapia
Neoplasias/complicações
Cuidados Paliativos
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Bilirrubina/sangue
Complemento C3/imunologia
Complemento C4/imunologia
Drenagem/métodos
Endotoxinas/sangue
Feminino
Seres Humanos
Isotipos de Imunoglobulinas/sangue
Isotipos de Imunoglobulinas/imunologia
Icterícia Obstrutiva/diagnóstico
Masculino
Meia-Idade
Imagem Multimodal
Neoplasias/diagnóstico
Cuidados Paliativos/métodos
Estudos Retrospectivos
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Complement C3); 0 (Complement C4); 0 (Endotoxins); 0 (Immunoglobulin Isotypes); RFM9X3LJ49 (Bilirubin)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170726
[St] Status:MEDLINE


  9 / 4772 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28707730
[Au] Autor:Suffritti C; Tobaldini E; Schiavon R; Strada S; Maggioni L; Mehta S; Sandrone G; Toschi-Dias E; Cicardi M; Montano N
[Ad] Endereço:Departments of Biomedical and Clinical Sciences 'L. Sacco', University of Milan, Milan, Italy.
[Ti] Título:Complement and contact system activation in acute congestive heart failure patients.
[So] Source:Clin Exp Immunol;190(2):251-257, 2017 Nov.
[Is] ISSN:1365-2249
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Recent experimental data indicate a pathogenic role of complement activation in congestive heart failure (CHF). The aim of this study was to evaluate contact and complement systems activation in patients hospitalized for an acute episode of CHF. Forty-two of 80 consecutive patients admitted at our hospital with confirmed diagnosis of acute CHF were enrolled. They underwent blood sampling within 24 h from admission (T0) and at clinical stability (T1). Patients were stratified for ejection fraction (EF) based on echocardiographic test. We measured plasma levels of C3, C4, sC5b-9 and cleaved high molecular weight kininogen (contact activation marker). At T1, C3 levels increased significantly compared to T0 (97 ± 2 versus 104 ± 3% of total pooled plasma, P < 0·01). Classifying patients according to EF, only patients with preserved EF presented a significant increase of C3 from T0 to T1 (99 ± 3 versus 108 ± 4%, P = 0·03). When the sample was stratified according to clinical outcome, C3 (98 ± 3 versus 104 ± 4%, P = 0·03) and sC5b-9 levels (204 ± 10 versus 230 ± 11 ng/ml, P = 0·03) were increased in patients who had positive outcome after hospitalization. CHF patients with preserved EF and positive outcome after hospitalization showed higher levels of sC5b-9 in the T1 period compared with T0 (211 ± 14 versus 243 ± 14 ng/ml, P = 0·04). Our results suggest that the complement system reacts differently if CHF occurs with preserved or reduced EF. This finding is interesting if we consider the difference in epidemiology, pathogenesis and possible therapeutic approaches of these two clinical entities.
[Mh] Termos MeSH primário: Ativação do Complemento
Insuficiência Cardíaca/imunologia
Insuficiência Cardíaca/fisiopatologia
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Complemento C3/análise
Complemento C4/análise
Complexo de Ataque à Membrana do Sistema Complemento/análise
Feminino
Insuficiência Cardíaca/diagnóstico
Hospitalização
Seres Humanos
Cininogênios/sangue
Masculino
Volume Sistólico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Complement C3); 0 (Complement C4); 0 (Complement Membrane Attack Complex); 0 (Kininogens)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171025
[Lr] Data última revisão:
171025
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170715
[St] Status:MEDLINE
[do] DOI:10.1111/cei.13011


  10 / 4772 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28637898
[Au] Autor:Vogt LM; Talens S; Kwasniewicz E; Scavenius C; Struglics A; Enghild JJ; Saxne T; Blom AM
[Ad] Endereço:Division of Medical Protein Chemistry, Department of Translational Medicine, Lund University, Skåne County Council, S-20502 Malmö, Sweden.
[Ti] Título:Activation of Complement by Pigment Epithelium-Derived Factor in Rheumatoid Arthritis.
[So] Source:J Immunol;199(3):1113-1121, 2017 Aug 01.
[Is] ISSN:1550-6606
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The aim of this study was to identify molecules that trigger complement activation in rheumatic joints. C4d, the final cleavage product of C4 activation, is found in the diseased joint and can bind covalently to complement-activating molecules. By using a highly specific Ab against a cleavage neoepitope in C4d, several molecules that were specifically bound to C4d were identified from pooled synovial fluid (SF) from four rheumatoid arthritis (RA) patients. One of these molecules, pigment epithelium-derived factor (PEDF), is a broadly expressed multifunctional member of the serine proteinase inhibitor family. Using ELISA, we confirmed the presence of various amounts of complexes between PEDF and C4d in the SF from 30 RA patients, whereas none were detected in SF from control subjects. Correlation analyses suggested that, in arthritis patients, C4d-PEDF complexes found in sera arise from the joints, as well as from other tissues, and levels of the complexes did not differ in sera of RA patients and healthy controls. When immobilized, recombinant PEDF expressed in eukaryotic cells activated the classical complement pathway but not the alternative or lectin pathways. C1q protein was demonstrated to bind immobilized PEDF, and PEDF was shown to bind to immobilized C1q, in particular its head regions, which are known to interact with other activators of the classical pathway. Our results call for further investigation into the role of PEDF in inflammatory processes in the joint, which, in combination with classical complement activation, appears to be part of a (patho-)physiologic response.
[Mh] Termos MeSH primário: Artrite Reumatoide/imunologia
Ativação do Complemento
Complemento C4/metabolismo
Proteínas do Olho/imunologia
Proteínas do Olho/metabolismo
Fatores de Crescimento Neural/imunologia
Fatores de Crescimento Neural/metabolismo
Serpinas/imunologia
Serpinas/metabolismo
Líquido Sinovial/química
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Artrite Reumatoide/fisiopatologia
Complemento C1q/metabolismo
Complemento C4/imunologia
Via Clássica do Complemento
Lectina de Ligação a Manose da Via do Complemento
Ensaio de Imunoadsorção Enzimática
Proteínas do Olho/sangue
Proteínas do Olho/genética
Feminino
Seres Humanos
Masculino
Meia-Idade
Fatores de Crescimento Neural/sangue
Fatores de Crescimento Neural/genética
Ligação Proteica
Serpinas/sangue
Serpinas/genética
Líquido Sinovial/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Complement C4); 0 (Eye Proteins); 0 (Nerve Growth Factors); 0 (Serpins); 0 (pigment epithelium-derived factor); 80295-33-6 (Complement C1q)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170623
[St] Status:MEDLINE
[do] DOI:10.4049/jimmunol.1700018



página 1 de 478 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde